Analysis Mithra Pharmaceuticals SA (0R91)
6/5/2024
Analysis of Mithra Pharmaceuticals SA (0R91)
Mithra Pharmaceuticals SA is showing a consistent price close at 0.22300 over the past few days. The Relative Strength Index (RSI) indicator is at 28.45, indicating the stock is approaching oversold conditions. The Moving Average Convergence Divergence (MACD) indicator is negative but showing signs of potential reversal with the MACD line crossing above the signal line.The Simple Moving Average (SMA) and Exponential Moving Average (EMA) are both around 0.223, suggesting stability in the stock price. However, the Weighted Moving Average (WMA) is slightly lower at 0.223, indicating some recent downward pressure.
Overall, Mithra Pharmaceuticals SA seems to be consolidating around the current price level with potential for a reversal in the MACD indicator. Traders may want to monitor the RSI for oversold conditions and the MACD for a bullish crossover as potential entry points.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a healthy current ratio, but a relatively high total debt to equity ratio. The profit margin and operating margin are both positive, indicating profitability. The company's fiscal year ends in September 2023, with notable figures such as revenue, EBITDA, and net income.
Moving on to stock statistics, key metrics include short ratio, float shares, shares outstanding, and percentages held by insiders and institutions. The company's stock price summary provides information on beta, moving averages, and the range of the stock price over the past year.
Valuation metrics show ratios such as PEG ratio, PE ratios, price to book, price to sales, and various enterprise value multiples. The market capitalization is also provided.
Lastly, dividends and splits data include payout ratio, dividend dates, split information, and dividend yield metrics. This information gives insights into the company's dividend policy and historical performance.
Income statement 💸
These are the revenues. Here are the conclusions based on the data provided:1. The company's sales revenue has been increasing over the years, from $274.52 billion in 2020 to $383.29 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from $104.96 billion to $169.15 billion.
3. Operating income has also shown an increasing trend, from $66.29 billion in 2020 to $114.30 billion in 2023.
4. Net income has been increasing steadily, from $57.41 billion in 2020 to $96.99 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years.
6. The company has been able to maintain a healthy EBITDA margin, with EBITDA ranging from $81.02 billion to $129.18 billion.
7. Despite an increase in income tax expenses, the company has managed to grow its net income consistently.
8. The company has been able to control its operating expenses effectively, as seen in the stable operating income figures.
9. Overall, the financial performance of the company seems to be on an upward trajectory, with increasing revenues and profitability over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key metrics over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for both the upcoming quarters and fiscal years.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate to healthy growth expected in both the short term and the long term.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, and analysts expect this growth to continue at a slightly lower but still healthy rate in the coming years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the median at $201.43. The current price of the security is $192.25, which is below both the average and median forecasted prices.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, from $323.9 billion in 2018 to $352.8 billion in 2023.
2. Current assets have fluctuated but show an overall increasing trend.
3. Non-current assets have also been increasing steadily.
4. Total liabilities have been increasing, but at a slower pace compared to total assets.
5. Shareholders' equity has been increasing, indicating a positive trend in the company's net worth.
6. The company has been investing more in non-current assets like investments and advances, machinery, furniture, and equipment.
7. The company has been relying more on long-term debt to finance its operations.
8. The company has been managing its current liabilities effectively, with a balanced mix of short-term debt and accounts payable.
9. The company has been maintaining a healthy cash position and short-term investments.
10. Overall, the financial health of the company seems to be improving, with a stronger balance sheet and increasing shareholders' equity.
MACD of 0R91
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
